-
São Paulo - O Icesp (Instituto do Câncer do Estado de São Paulo) divulgou nesta sexta-feira (4) os finalistas da 16ª edição do Prêmio Octavio Frias de Oliveira, que reconhece pesquisas e inovações em oncologia no Brasil. A iniciativa, em parceria com a Folha, destaca trabalhos que avançam no combate ao câncer, como novas terapias, tecnologias e descobertas genéticas.
Entre os [...]
-
São Paulo - O Icesp (Instituto do Câncer do Estado de São Paulo) divulgou nesta sexta-feira (4) os finalistas da 16ª edição do Prêmio Octavio Frias de Oliveira, que reconhece pesquisas e inovações em oncologia no Brasil. A iniciativa, em parceria com a Folha, destaca trabalhos que avançam no combate ao câncer, como novas terapias, tecnologias e descobertas genéticas.
Entre os [...]
-
Un grupo liderado por investigadores del A.C. Camargo Cancer Center logró mejorar las células CAR-T, haciéndolas más eficaces en el tratamiento de tipos refractarios de linfoma y leucemia.
Actualmente, la mitad de los pacientes con linfoma no Hodgkin y con leucemia linfoblástica aguda –dos tipos de cáncer que afectan a las células sanguíneas– no responden adecuadamente al tratamiento con células CAR-T. Esta terapia [...]
-
Currently, half of patients with non-Hodgkin’s lymphoma and acute lymphoblastic leukemia – two types of cancer that affect blood cells – do not respond adequately to treatment with CAR T cells. The therapy involves harvesting the patient’s own defense cells (T lymphocytes), modifying them in the laboratory to make them capable of destroying tumor cells and reinjecting them into the body. These refractory cases usually relapse after conventional immunotherapy.
To [...]
-
Currently, half of patients with non-Hodgkin’s lymphoma and acute lymphoblastic leukemia—two types of cancer that affect blood cells—do not respond adequately to treatment with CAR-T cells. The therapy involves harvesting the patient’s own defense cells (T lymphocytes), modifying them in the laboratory to make them capable of destroying tumor cells, and reinjecting them into the body. These refractory cases usually relapse after conventional immunotherapy.
To [...]
-
Currently, half of patients with non-Hodgkin’s lymphoma and acute lymphoblastic leukaemia – two types of cancer that affect blood cells – do not respond adequately to treatment with CAR-T cells.
The therapy involves harvesting the patient’s own defence cells (T lymphocytes), modifying them in the laboratory to make them capable of destroying tumour cells, and reinjecting them into the body.
These refractory cases usually relapse after conventional immunotherapy [...]
-
Currently, half of patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia—two types of cancer that affect blood cells—do not respond adequately to treatment with CAR-T cells. The therapy involves harvesting the patient's own defense cells (T lymphocytes), modifying them in the laboratory to make them capable of destroying tumor cells, and reinjecting them into the body. These refractory cases usually relapse after conventional immunotherapy.
To overcome [...]
-
In the evolving landscape of cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a beacon of hope, particularly in hematological malignancies such as non-Hodgkin’s lymphoma and acute lymphoblastic leukemia. Despite its groundbreaking potential, approximately fifty percent of patients afflicted with these blood cancers exhibit resistance or an inadequate response to the current CAR-T cell treatments. This significant therapeutic gap underscores an urgent need [...]
-
In the evolving landscape of cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a beacon of hope, particularly in hematological malignancies such as non-Hodgkin’s lymphoma and acute lymphoblastic leukemia. Despite its groundbreaking potential, approximately fifty percent of patients afflicted with these blood cancers exhibit resistance or an inadequate response to the current CAR-T cell treatments. This significant therapeutic gap underscores an urgent need [...]
-
Gizmodo
- Publicado em 20 de abril de 2025
Grupo liderado por pesquisadores do A.C. Camargo Cancer Center obteve sucesso na melhoria de células CAR-T, tornando-as mais eficazes no tratamento de tipos refratários de linfoma e leucemia
Texto: André Julião | Agência FAPESP
Atualmente, metade dos pacientes com linfoma não Hodgkin e com leucemia linfoblástica aguda – dois tipos de câncer que afetam células do sangue – não responde adequadamente ao [...]
